- Home
- DPG vs CBIO Comparison
DPG vs CBIO Comparison
Compare DPG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DPG | CBIO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.2M | 537.5M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DPG | CBIO |
|---|---|---|
| Price | $14.58 | $17.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 48.3K | ★ 170.0K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,500.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.36 | $8.72 |
| 52 Week High | $15.15 | $27.41 |
Technical Indicators
Market Signals| Indicator | DPG | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 55.82 |
| Support Level | $14.37 | $16.77 |
| Resistance Level | $14.77 | $17.93 |
| Average True Range (ATR) | 0.17 | 1.00 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 66.69 | 69.06 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.